| Literature DB >> 35136081 |
José Miguel Sousa1,2, Hugo Ribeiro3, João Luís Silva3, Paulo Nogueira4, José Guimarães Consciência3,5.
Abstract
This meta-analysis aims to determine the clinical outcomes, complications, and fusion rates in endoscopic assisted intra-foraminal lumbar interbody fusion (iLIF) and minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) for lumbar degenerative diseases. The MEDLINE, Embase, and Cochrane Library databases were searched. The inclusion criteria were: five or more consecutive patients who underwent iLIF or MI-TLIF for lumbar degenerative diseases; description of the surgical technique; clinical outcome measures, complications and imaging assessment; minimum follow-up of 12 months. Surgical time, blood loss, and length of hospital stay were extracted. Mean outcome improvements were pooled and compared with minimal clinically important differences (MCID). Pooled and direct meta-analysis were evaluated. We identified 42 eligible studies. The iLIF group had significantly lower mean intra-operative blood loss, unstandardized mean difference (UMD) 110.61 mL (95%CI 70.43; 150.80; p value < 0.0001), and significantly decreased length of hospital stay (UMD 2.36; 95%CI 1.77; 2.94; p value < 0.0001). Visual analogue scale (VAS) back, VAS leg and Oswestry disability index (ODI) baseline to last follow-up mean improvements were statistically significant (p value < 0.0001), and clinically important for both groups (MCID VAS back > 1.16; MCID VAS leg > 1.36; MCID > 12.40). There was no significant difference in complication nor fusion rates between both cohorts. Interbody fusion using either iLIF or MI-TLIF leads to significant and clinically important improvements in clinical outcomes for lumbar degenerative diseases. Both procedures provide high rates of fusion at 12 months or later, without significant difference in complication rates. iLIF is associated with significantly less intraoperative blood loss and length of hospital stay. Study registration: PROSPERO international prospective register of systematic reviews: Registration No. CRD42020180980, accessible at https://www.crd.york.ac.uk/prospero/ April 2020.Entities:
Mesh:
Year: 2022 PMID: 35136081 PMCID: PMC8825843 DOI: 10.1038/s41598-022-05988-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1PRISMA flowchart of systematic review and meta-analysis comparing clinical outcomes and complications in endoscopic assisted intraforaminal lumbar interbody fusion (iLIF) versus minimally invasive transforaminal lumbar interbody fusion (MI-TLIF).
Characteristics of included studies.
| Study (Level of evidence) | Journal (Year) | Years of study enrollment | MINORS score | Approach | Disease | No. of patients | Male (%) |
|---|---|---|---|---|---|---|---|
| Park et al. (IV) | Asian Spine J (2011) | – | 13 | MI-TLIF | DSP, DST | 66 | 30 |
| Rouben et al. (IV) | J Spinal Disord Tech (2011) | 2002–2006 | 13 | MI-TLIF | DDD, DSP, DST | 169 | 43 |
| Lee et al. (II) | Eur Spine J (2012) | 2002–2008 | 22 | MI-TLIF | DSP, DDD, DST | 72 | 28 |
| Lee et al. (IV) | Spine (2012) | – | 14 | MI-TLIF | DST, DSP, DDD | 86 | 52 |
| Saetia et al. (III) | J Med Assoc Thai (2013) | 2008–2009 | 13 | MI-TLIF | DSP | 12 | 8 |
| Seng et al. (III) | Spine (2013) | 2004–2007 | 22 | MI-TLIF | DDD, DSP, DST | 40 | 17 |
| Gu et al. (II) | Int Orthop (2014) | 2010–2011 | 21 | MI-TLIF | DDD, DST | 44 | 43 |
| Lee et al. (II) | J Spinal Disord Tech (2014) | 2005–2009 | 14 | MI-TLIF | DDD, DSP, DST | 90 | 29 |
| Min et al. (III) | Asian Spine J (2014) | 2006–2011 | 18 | MI-TLIF | DDD, DSP, DST | 30 | 37 |
| Shen et al. (III) | J Clin Neurosci (2014) | 2009–2011 | 19 | MI-TLIF | DDD, DST | 34 | 47 |
| Adogwa et al. (III) | World Neurosurg (2015) | 2003–2010 | 20 | MI-TLIF | DDD, DSP, DST | 40 | 50 |
| Brodano et al. (III) | J Spinal Disord Tech (2015) | 2006–2010 | 21 | MI-TLIF | DDD, DSP | 30 | 60 |
| Kuo et al. (III) | Neurosurg focus (2016) | 2007–2012 | 22 | MI-TLIF | DSP | 22 | 27 |
| Li et al. (II) | J Spinal Disord Tech (2015) | 2008–2009 | 22 | MI-TLIF | DDD, DSP, DST | 95 | 48 |
| Yang et al. (II) | Int J Clin Exp Med (2015) | – | 24 | MI-TLIF | DDD, DSP, DST | 50 | 36 |
| Fan et al. (III) | J Clin Neurosci (2016) | 2010–2014 | 22 | MI-TLIF | DSP | 78 | 60 |
| Gao et al. (III) | Biomed Res. (2016) | 2011–2014 | 19 | MI-TLIF | DDD, DSP | 75 | 40 |
| Kim et al. (IV) | World Neurosurg (2016) | 2011–2013 | 14 | MI-TLIF | DDD, DSP | 50 | 44 |
| Shen et al. (II) | Clin Spine Surg (2016) | 2009–2011 | 20 | MI-TLIF | DDD | 34 | 47 |
| Lv et al. (III) | Minim Invasive Ther Allied Technol (2017) | 2010–2012 | 20 | MI-TLIF | DDD | 50 | – |
| Razak et al. (IV) | Asian Spine J (2017) | 2004–2009 | 14 | MI-TLIF | DSP | 56 | 29 |
| Serban et al. (II) | Biomed Res Int (2017) | 2011–2015 | 19 | MI-TLIF | DSP, ISP | 40 | 40 |
| Yang et al. (IV) | Int J Clin Exp Med (2017) | 2010–2014 | 14 | MI-TLIF | DSP, DST | 65 | 51 |
| Yang et al. (II) | J Orthop Traumatol (2017) | – | 21 | MI-TLIF | DSP, DST | 21 | 33 |
| Zhang et al. (III) | Medicine (2017) | 2012–2014 | 19 | MI-TLIF | DSP, ISP | 26 | 42 |
| Wu et al. (III) | Ann Transl Med (2018) | 2010–2015 | 17 | MI-TLIF | DSP, ISP | 79 | 42 |
| Wu et al. (IV) | Biomed Res Int (2018) | – | 11 | iLIF | DSP, ISP | 6 | 50 |
| Zhao et al. (III) | Int Orthop. (2018) | 2014–2015 | 20 | MI-TLIF | DST, DSP, ISP | 129 | 50 |
| Goh et al. (III) | Clin Orthop Relat Res (2019) | 2012–2014 | 20 | MI-TLIF | DSP | 78 | 24 |
| Kolcun et al. (IV) | Neurosurg Focus (2019) | 2014–2017 | 13 | iLIF | DDD, DSP | 100 | 44 |
| Lin et al. (III) | Neurol Med Chit (Tokyo) (2019) | 2010–2013 | 20 | MI-TLIF | DDD | 34 | 26 |
| Mokawem et al. (III) | J Clin Neurosci (2019) | 2015–2017 | 20 | MI-TLIF | DDD, DSP, DST, DSS | 50 | – |
| Shen (IV) | World Neurosurg (2019) | – | 12 | iLIF | DSP, DST | 18 | – |
| Yang et al. (IV) | Biomed Res Int (2019) | 2016–2017 | 12 | iLIF | DST | 7 | 14 |
| Zhao et al. (IV) | J. Orthop. Surg. Res. (2018) | 2008–2014 | 12 | MI-TLIF | DSS | 22 | 36 |
| Zhao et al. (III) | Eur J Inflamm (2019) | 2014–2015 | 19 | MI-TLIF | DDD, DST | 45 | – |
| Ao et al. (II) | Int J Surg. (2020) | 2018 | 22 | Both | DSP, DST | 75 | 51 |
| Chan et al. (III) | Neurosurgery. (2020) | 2014–2016 | 22 | MI-TLIF | DSP | 72 | 44 |
| El Mansy et al. (III) | Musculoskelet Surg. (2020) | 2011–2014 | 22 | MI-TLIF | DDD, DST | 15 | 60 |
| Jin et al. (IV) | Pain Physician (2020) | 2016–2017 | 10 | iLIF | DDD, DST | 39 | 64 |
| Kim et al. (III) | Clin. Spine Surg. (2020) | 2015–2018 | 21 | MI-TLIF | DSP, ISP | 55 | 45 |
| Wang et al. (IV) | J Int Med Res (2020) | 2016–2017 | 11 | MI-TLIF | DSP, DST | 122 | 37 |
DDD degenerative disk disease, DSP degenerative spondylolisthesis, ISP isthmic spondylolisthesis, DST degenerative spinal stenosis, DSC degenerative spinal scoliosis, VAS Visual Analogue Scale, ODI Oswestry Disability Index, NSS Neurogenic Symptom Score, SF-36 short form 36, NASS North American Spine Society scores for neurogenic symptoms, JOA Japanese Orthopaedic Association scores, EQ-5D Euro-Qol-5 dimension questionnaire.
Estimation of the pooled means and prevalences for surgical mean time, blood loss, hospital stay, complications, revision and fusion in iLIF studies.
| Author | N | Surgical mean time | Blood loss | Hospital stay | |||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | ||
| Wu et al. | 6 | 167.5 | 30.9 | 70 | 24.5 | 1.2 | 0.6 |
| Kolcun et al. | 100 | 91. 48 | 27.57 | 66.89 | 71.71 | 1.4 | 1 |
| Shen et al. | 18 | 168 | 46 | 35 | 21 | 1.2 | 0.8 |
| Yang et al. | 7 | 285.7 | 15.9 | 117.1 | 86.1 | 4 | 1.07 |
| Jin et al. | 39 | 213.8 | 31.7 | 25 | 12.6 | 6.7 | 0.9 |
| Pooled ⍬ (95% CI) | 138.32 (133.70, 142.95) | 56.08 (47.27, 64.89) | 2.70 (2.55, 2.84) | ||||
| 0.996 | 0.9294 | 0.996 | |||||
| N | 170 | 170 | 170 | 170 | |||
Estimation of the pooled means and prevalences for surgical mean time, blood loss, hospital stay, complications, revision and fusion in MI-TLIF studies.
| Author | N | Surgical mean time | Blood loss | Hospital stay | |||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | ||
| Park et al. | 66 | ||||||
| Rouben | 169 | 183 | 63 | 171 | 107 | 0.6 | 14 |
| Lee et al. | 72 | 166.4 | 52.1 | 50.6 | 161 | 3.2 | 2.9 |
| Lee | 86 | 209.03 | 32.23 | 371.2 | 279.28 | ||
| Saetia | 12 | 340 | 81.49 | 317 | 195.79 | 8.42 | 3.34 |
| Seng | 40 | 185 | 8.7 | 127.3 | 45.7 | 3.6 | 0.3 |
| Gu et al. | 44 | 195.5 | 28 | 248.4 | 94.3 | 9.3 | 3.7 |
| Lee | 90 | 159.1 | 37.48 | 130 | 122.79 | 2.9 | 1.22 |
| Min | 30 | 156 | 5.99 | 397.5 | 43.02 | ||
| Shen et al. | 34 | 143.1 | 22.5 | 106.3 | 53.8 | 6.6 | 2.1 |
| Adogwa et al. | 40 | ||||||
| Brodano et al. | 30 | 144 | 230 | 4.1 | |||
| Kuo et al. | 22 | 270 | 78 | 232.5 | 194.2 | ||
| Li et al. | 95 | 164.8 | 9.2 | ||||
| Yang et al. | 50 | 178.5 | 17.7 | 183.9 | 24.2 | ||
| Fan et al. | 78 | 184.87 | 45.01 | 289.74 | 154.18 | 15.99 | 4.11 |
| Gao et al. | 75 | 191 | 3.2 | 195 | 203 | ||
| Kim et al. | 50 | 266.4 | 84.3 | 112.76 | 61.73 | 2.5 | 1.7 |
| Shen et al. | 34 | ||||||
| Lv et al. | 50 | 103.2 | 16.9 | 143.1 | 37.4 | 5.4 | 2.8 |
| Razak et al. | 56 | 167 | 49 | 126 | 107 | 2.8 | 11 |
| Serban et al. | 40 | 321.92 | 85.57 | 351.25 | 198.87 | 1.92 | 0.52 |
| Yang et al. | 65 | 184.26 | 20.69 | 190.95 | 28.06 | ||
| Yang et al. | 21 | 179 | 20.7 | 188.6 | 42.3 | ||
| Zhang et al. | 26 | 93 | 25 | 115 | 37 | 4.3 | 1.3 |
| Wu et al. | 79 | 145.5 | 21.5 | 163.7 | 49.6 | 5.8 | 1.4 |
| Zhao et al. | 129 | 154.8 | 37.95 | 212.22 | 80.98 | 8.04 | 1.97 |
| Goh et al. | 78 | 148 | 34.5 | 9 | 1 | ||
| Lin et al. | 34 | 167.1 | 39.1 | 225.2 | 94.1 | 7.8 | 2.3 |
| Mokawem et al. | 50 | ||||||
| Zhao et al. | 22 | 153.3 | 26.3 | 175 | 83.4 | 5.4 | 0.9 |
| Zhao et al. | 45 | ||||||
| Chan et al. | 72 | 228.2 | 111.5 | 108.8 | 85.6 | 2.9 | 1.8 |
| El Mansy et al. | 15 | ||||||
| Kim et al. | 55 | 173 | 47.1 | 9.1 | 2.9 | ||
| Wang et al. | 122 | 130.48 | 34.44 | 114.1 | 96.7 | 6.45 | 2.47 |
| Pooled ⍬ (95% CI) | 176.44 (174.28, 178.60) | 184.88 (178.69, 191.07) | 5.31 (5.00, 5.63) | ||||
| 99.3% | 98.3% | 99.15% | |||||
| N | 2076 | 1796 | 1568 | 1352 | |||
Unstandardized mean differences surgical time, blood loss and length of stay between MI-TLIF and iLIF.
| Author | MI-TLIF | iLIF | UMD | 95% CI | |||||
|---|---|---|---|---|---|---|---|---|---|
| N | Mean | SD | N | Mean | SD | ||||
| Ao et al. | 40 | 103.6 | 17.79 | 35 | 143 | 24.2 | − 39.4 | (− 49.1, − 29.64) | < 0.0001* |
| Pooled study | 1796 | 176.4 | 46.75 | 170 | 138.3 | 30.72 | 38.12 | (33.01, 43.23) | < 0.0001* |
| UMD (95% CI); I2 | − 0.51 (− 76.45, 75.43); 99% | 0.99 | |||||||
| Ao et al. | 40 | 171.8 | 84.29 | 35 | 84.29 | 44.34 | 87.5 | (57.53, 117.47) | < 0.0001* |
| Pooled study | 1568 | 184.9 | 125.1 | 170 | 56.08 | 58.78 | 128.8 | (118.01, 139.59) | < 0.0001* |
| UMD (95% CI); I2 | 110.61 (70.43, 150.80); 85% | < 0.0001* | |||||||
| Ao et al. | 40 | 5.11 | 1.44 | 35 | 3.11 | 1.18 | 2 | (1.41, 2.59) | < 0.0001* |
| Pooled study | 1352 | 5.31 | 5.87 | 170 | 2.7 | 0.95 | 2.61 | (2.27, 2.95) | < 0.0001* |
| UMD (95% CI); I2 | 2.36 (1.77, 2.94); 67% | < 0.0001* | |||||||
Significant values are in asterisk.
Figure 2Comparison of blood loss (a), length of stay (b) and complications (c).
Estimation of the pooled means for clinical outcomes in iLIF studies.
| Author | N | VAS back | VAS leg | ODI | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-op | Post-op | Pre-op | Post-op | Pre-op | Post-op | ||||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | ||
| Wu et al. | 6 | 6.17 | 0.75 | 0.67 | 0.52 | 5.33 | 1.97 | 0.17 | 0.41 | 44.83 | 4.75 | 11.17 | 4.31 |
| Kolcun et al. | 100 | – | – | – | – | – | – | – | – | 29.6 | 15.3 | 17.2 | 16.9 |
| Shen et al. | 18 | 8.1 | 2 | 1.8 | 0.9 | – | – | – | – | 48 | 14 | 13 | 11 |
| Yang et al. | 7 | 7.4 | 0.73 | 0.9 | 0.64 | 6.14 | 1.64 | 0.71 | 0.45 | 53.57 | 9.5 | 16.6 | 7 |
| Jin et al. | 39 | 5.7 | 0.8 | 0.7 | 0.2 | 7.9 | 0.5 | 1 | 0 | 43.1 | 4.9 | 16.1 | 7.2 |
| Pooled ⍬ (95% CI) | 6.53 (6.24, 6.81) | 1.00 (0.87.1.13) | 7.37 (7.1, 7.64) | 0.87 (0.73, 1) | 36.17 (34.22, 38.12) | 16.27 (14.16, 18.37) | |||||||
| I2 | 94.0% | 88.8% | 88.8% | 90.3% | 95.2% | 51.5% | |||||||
| N | 170 | 70 | 70 | 52 | 52 | 170 | 170 | ||||||
Estimation of the pooled means for clinical outcomes in MI-TLIF studies.
| Author | N | VAS back | VAS leg | ODI | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-op | Post-op | Pre-op | Post-op | Pre-op | Post-op | ||||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | ||
| Park et al | 66 | 8.1 | 2 | 2.6 | 2.1 | 8.1 | 2 | 1.6 | 2.8 | 60.2 | 16.5 | 25.9 | 17.9 |
| Rouben | 169 | 6.9 | 1.45 | 2.67 | 1.96 | 69.3 | 13.5 | 29.2 | 20.5 | ||||
| Lee et al | 72 | 6.3 | 2.9 | 2.3 | 3 | 5.8 | 3.3 | 1.6 | 2.7 | 48.1 | 18.8 | 21.4 | 20.9 |
| Lee | 86 | 5.5 | 2.68 | 1.78 | 2.08 | 6.8 | 2.35 | 0.62 | 1.2 | 23.7 | 6.25 | 8.81 | 6.85 |
| Saetia | 12 | 8.75 | 1.6 | 2.08 | 1.41 | 61.8 | 12.89 | 49.55 | 11.24 | ||||
| Seng | 40 | 5.6 | 3.3 | 1.3 | 0.4 | 5.9 | 2.8 | 0.8 | 0.4 | 41.3 | 20.1 | 13.6 | 2.8 |
| Gu et al | 44 | 7.3 | 1.2 | 1.9 | 0.7 | 7.6 | 0.9 | 1.7 | 0.6 | 43.7 | 4.3 | 16.5 | 2 |
| Lee | 90 | 6.15 | 2.76 | 2.09 | 2.84 | 5.59 | 3.26 | 1.36 | 2.34 | 46.18 | 19.13 | 19.67 | 19.28 |
| Min | 30 | 7.17 | 0.61 | 0.57 | 0.2 | 23.53 | 2.73 | 7.73 | 1.95 | ||||
| Shen et al | 34 | 7.2 | 2.1 | 2.2 | 1.4 | 51.58 | 16.38 | 22.84 | 15.65 | ||||
| Adogwa et al | 40 | 6.97 | 2.49 | 2.42 | 3.81 | 7.07 | 3 | 3.77 | 4.53 | 50.18 | 16.74 | 11.61 | 25.52 |
| Brodano et al | 30 | 7.8 | 1.4 | 2.3 | 1.3 | 42 | 6.2 | 10 | 6.6 | ||||
| Kuo et al | 22 | 6.9 | 2.1 | 2.9 | 2.6 | 6 | 2.9 | 2.1 | 2.3 | 23 | 7.7 | 9.9 | 7.1 |
| Li et al | 95 | 7.7 | 0.4 | 2.5 | 0.6 | 6.7 | 0.6 | 3.2 | 0.7 | 79.8 | 4.4 | 30.3 | 4.3 |
| Yang et al | 50 | 5.1 | 1.7 | 0.8 | 0.8 | 5.8 | 1.5 | 0.8 | 0.8 | 50.7 | 14.5 | 11.6 | 6.3 |
| Fan et al | 78 | 7.22 | 0.62 | 3.4 | 0.59 | 49.36 | 9.72 | 17.2 | 5.27 | ||||
| Gao et al | 75 | 7.3 | 1.2 | 1.7 | 1.1 | 56.3 | 14.7 | 16.8 | 8 | ||||
| Kim et al | 50 | 7.2 | 2.4 | 3.5 | 2.9 | 5.2 | 3.5 | 1.6 | 2.7 | 51 | 16.6 | 29.2 | 16.9 |
| Shen et al | 34 | 7.2 | 2.1 | 2.2 | 1.4 | 51.58 | 16.38 | 22.84 | 15.65 | ||||
| Lv et al | 50 | 6.81 | 0.8 | 2.36 | 0.29 | 7.8 | 0.9 | 2.38 | 0.41 | 58 | 8.8 | 14.2 | 3.3 |
| Razak et al | 56 | 7 | 3 | 2 | 3 | 6 | 3 | 1 | 3 | 47 | 20 | 16 | 19 |
| Serban et al | 40 | 37.75 | 6.59 | 11.52 | 6.56 | ||||||||
| Yang et al | 65 | 5.03 | 1.61 | 0.8 | 0.87 | 5.83 | 1.44 | 0.64 | 0.84 | 51.05 | 13.81 | 12.14 | 9.04 |
| Yang et al | 21 | 5.8 | 0.9 | 1 | 0.9 | 5.2 | 1.3 | 0.6 | 0.7 | 43.5 | 15.1 | 12 | 6.4 |
| Zhang et al | 26 | 7.5 | 1.7 | 1 | 0.6 | 48.6 | 7 | 11.8 | 2.8 | ||||
| Wu et al | 79 | 6.78 | 1.48 | 1.63 | 1.2 | 7.12 | 1.33 | 1.77 | 1.39 | 60.7 | 10.6 | 25.3 | 6.3 |
| Zhao et al | 129 | 5.32 | 0.59 | 1.46 | 0.34 | 6.09 | 0.52 | 1.66 | 0.26 | 53.97 | 13.25 | 14.73 | 6.25 |
| Goh et al | 78 | 5.5 | 2.55 | 1 | 1.58 | 6 | 3 | 0 | 1 | 49 | 16 | 11.5 | 11.77 |
| Lin et al | 34 | 50.8 | 9.7 | 17.1 | 8.1 | ||||||||
| Mokawem et al | 50 | 7.4 | 3.05 | 1.9 | 1.46 | 7.9 | 2.67 | 1.2 | 1.57 | 61.1 | 21.22 | 18.1 | 12.92 |
| Zhao et al | 22 | 6.2 | 1.8 | 2.2 | 0.7 | 8.2 | 0.7 | 1.4 | 1.4 | 62.4 | 16.1 | 24.2 | 9.3 |
| Zhao et al | 45 | 7.3 | 1.5 | 2 | 1.9 | 5.2 | 1.1 | 1.1 | 0.8 | 54.25 | 12.76 | 22.78 | 13.69 |
| Chan et al | 72 | 6.9 | 2.6 | 2.3 | 2.9 | 6.3 | 2.8 | 1.6 | 2.7 | 46.2 | 16.3 | 14.3 | 17.2 |
| El Mansy et al | 15 | 6.87 | 1.25 | 2.6 | 1.12 | 5.07 | 1.94 | 2.33 | 0.72 | 29.73 | 7.44 | 7.47 | 5.18 |
| Kim et al | 55 | 6.5 | 1.5 | 1.9 | 0.8 | 7.8 | 1.7 | 1.8 | 0.8 | 69.6 | 6.2 | 16.3 | 11.9 |
| Wang et al | 122 | 3.74 | 2.28 | 0.65 | 0.85 | 4.93 | 2.68 | 0.36 | 0.83 | 59.09 | 22.34 | 17.04 | 8.49 |
| Pooled ⍬ (95% CI) | 6.46 (6.37, 6.55) | 1.96 (1.88, 2.04) | 6.36 (6.24, 6.47) | 1.41 (1.32, 1.50) | 53.31 (52.69, 53.94) | 18.54 (17.98, 19.1) | |||||||
| 97.9% | 97.7% | 95.9% | 98.8% | 99.6% | 98.3% | ||||||||
| N | 2076 | 1946 | 1946 | 1518 | 1518 | 2050 | 2050 | ||||||
Unstandardized mean differences and baseline to last follow-up mean differences of VAS back, leg and ODI between MI-TLIF and iLIF.
| Author | MI-TLIF | iLIF | UMD | 95% CI | |||||
|---|---|---|---|---|---|---|---|---|---|
| N | Mean | SD | N | Mean | SD | ||||
| Ao et al | 40 | 5.53 | 1.88 | 35 | 5.09 | 2.09 | 0.44 | (− 0.46, 1.34) | 0.34 |
| Pooled study | 1946 | 6.46 | 1.97 | 70 | 6.53 | 1.22 | − 0.07 | (− 0.37, 0.23) | 0.83 |
| UMD (95% CI); I2 | 0.0 (− 0.34, 0.34); 9% | 0.99 | |||||||
| Ao et al | 40 | 1.31 | 1.08 | 35 | 1.18 | 0.95 | 0.13 | (− 0.33, 0.59) | 0.58 |
| Pooled study | 1946 | 1.96 | 1.77 | 70 | 1 | 0.54 | 0.96 | (0.81, 1.11) | < 0.0001* |
| UMD (95% CI); I2 | 0.57 (− 0.24, 1.39); 91% | 0.17 | |||||||
| Ao et al | 40 | 4.22 | – | 35 | 3.91 | – | – | – | – |
| Pooled study | 1946 | 4.5 | – | 70 | 5.53 | – | – | – | – |
| Ao et al | 40 | 5.65 | 1.55 | 35 | 6.11 | 1.83 | − 0.46 | (− 1.23, 0.31) | 0.24 |
| Pooled study | 1518 | 6.36 | 2.25 | 52 | 7.37 | 0.96 | − 1.01 | (− 1.29. − 0.73) | < 0.0001* |
| UMD (95% CI); I2 | − 0.86 (− 1.34. − 0.37); 42% | 0.0005* | |||||||
| Ao et al | 40 | 0.79 | 0.86 | 35 | 0.82 | 0.8 | − 0.03 | (− 0.41, 0.35) | 0.88 |
| Pooled study | 1518 | 1.41 | 1.76 | 52 | 0.87 | 0.49 | 0.54 | (0.38, 0.79) | < 0.0001* |
| UMD (95% CI); I2 | 0.28 (− 0.27, 0.84); 87% | 0.32 | |||||||
| Ao et al | 40 | 4.86 | – | 35 | 5.29 | – | – | – | – |
| Pooled study | 1518 | 4.95 | – | 52 | 6.5 | – | – | – | – |
| Ao et al | 40 | 56.9 | 11.5 | 35 | 53.94 | 10.87 | 2.96 | (− 2.11, 8.03) | 0.26 |
| Pooled study | 2050 | 53.31 | 14.5 | 170 | 36.17 | 13.04 | 17.14 | (15.09, 19.19) | < 0.0001* |
| UMD (95% CI); I2 | 10.25 (− 3.64, 24.14); 96% | 0.15 | |||||||
| Ao et al | 40 | 13.59 | 5.43 | 35 | 12.94 | 4.93 | 0.65 | (-1.70, 3.00) | 0.59 |
| Pooled study | 2050 | 18.54 | 12.88 | 170 | 16.27 | 14.08 | 2.27 | (0.07, 4.47) | 0.042* |
| UMD (95% CI); I2 | 1.52 (− 0.08, 3.12); 0% | 0.06 | |||||||
| Ao et al | 40 | 43.31 | – | 35 | 41 | 8.43 | – | – | – |
| Pooled study | 2050 | 34.77 | – | 180 | 19.9 | 13.56 | – | – | – |
*△ Baseline to last follow-up mean variation.
Prevalence of complications, revision and fusion in MI-TLIF and iLIF.
| iLIF (N = 170) | MI-TLIF (N = 2076) | |||
|---|---|---|---|---|
| Overall complications | 8 | 4.7% | 199 | 9.6% |
| Dural tear | 0 | 0.0% | 28 | 14.1% |
| Infection | 1 | 0.6% | 24 | 12.1% |
| Neurologic injury | 0 | 0.0% | 5 | 2.5% |
| Intraspinal haematoma | 0 | 0.0% | 3 | 1.5% |
| Radiculopathy | 0 | 0.0% | 6 | 3.0% |
| Dysesthesia | 0 | 0.0% | 2 | 1.0% |
| Cage subsidence | 0 | 0.0% | 14 | 7.0% |
| Cage migration | 2 | 1.2% | 11 | 5.5% |
| Screw malpositioning | 1 | 0.6% | 34 | 17.1% |
| Adjacent segment degeneration | 0 | 0.0% | 29 | 14.6% |
| Others | 4 | 2.4% | 43 | 21.6% |
| Revision | 2 | 1.2% | 50 | 2.4% |
| Fusion | 170 | 100.0% | 1933 | 93.1% |
Comparison of prevalence of complications and fusion between MI-TLIF and iLIF.
| Author | MI-TLIF | iLIF | OR | 95% CI | |||
|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | ||||
| Ao et al | 1 | 39 | 1 | 34 | 0.87 | (0.05, 14.48) | 0.924 |
| Pooled study | 199 | 1877 | 8 | 162 | 2.15 | (1.04, 4.43) | 0.033 |
| OR (95% CI); | 2.03 | (1.01, 4.09); 0% | 0.05 | ||||
| Ao et al | 36 | 4 | 29 | 6 | 1.86 | (0.48, 7.23) | 0.364 |
| Pooled study | 1933 | 117 | 170 | 0 | 0.05 | (0.00, 0.78) | < 0.001 |
| OR (95% CI); | 0.37 | (0.01, 12.95); 81% | 0.58 | ||||